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ABSTRACT
Several new methods to detect drug resistance in Mycobacterium tuberculosis have been proposed in
recent years. Colourimetric methods that use redox indicators or the nitrate reduction assay have
received increasing attention because of their simplicity and the absence of any requirement for
sophisticated equipment or highly trained personnel. Several studies have evaluated their accuracy and
performance in comparison with reference standard methods, particularly for the detection of resistance
to rifampicin and isoniazid, which are the two most important drugs used for the treatment of
tuberculosis. This review describes the development, evaluation and implementation of these methods
as rapid alternative tests for the detection of multidrug resistance in M. tuberculosis. Based on published
evidence and the high accuracy of colourimetric methods for detecting drug resistance in M. tuberculosis,
these methods seem to be appropriate for implementation in high-burden low-resource countries.
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INTRODUCTION
According to WHO estimates, two billion indi-
viduals, i.e., approximately one-third of the
world’s population, are infected latently with
Mycobacterium tuberculosis. The latest WHO report
states that there were 8.9 million new cases of
tuberculosis (TB) in 2004, and 1.7 million deaths
were attributed to the disease [1]. This scenario is
compounded by the human immunodeficiency
virus pandemic, with about one-third of the
40 million individuals currently infected with
human immunodeficiency virus being co-infected
with TB [2]. Most importantly, the emergence of
multidrug-resistant TB (MDRTB), defined as
resistance to at least isoniazid and rifampicin,
which are two essential drugs used for the
treatment of TB, is a major problem in the control
of the disease. The latest report on worldwide
anti-TB drug resistance, prepared by the
WHO ⁄ IUATLD Global Project on anti-TB drug
resistance surveillance, states that MDRTB has
reached levels of up to 14% among new patients,
and levels as high as 50% among previously
treated patients in some settings [3]. Moreover,
the recent description of ‘extensively drug-resist-
ant’ strains, defined as strains with resistance to at
least isoniazid and rifampicin, plus resistance to
any fluoroquinolone and either aminoglycosides
(amikacin, kanamycin) or capreomycin, stresses
the need to also investigate resistance to second-
line drugs [4,5]. Thus, early detection of resistance
to first- and second-line drugs in M. tuberculosis
represents a major priority for TB control
programmes.
Because of the long period required by con-
ventional methods to detect drug resistance in
M. tuberculosis [6], several new approaches have
been proposed during the last decade for the
rapid and early detection of drug resistance in
cases of TB. These techniques can be differenti-
ated into genotypic and phenotypic methods.
Genotypic methods search for genetic determi-
nants of resistance rather than the resistance
phenotype, and generally involve nucleic acid
amplification to detect genome mutations known
to be associated with drug resistance, while
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phenotypic methods rely on detection of growth
in the presence of the antibiotic(s) being tested
[7,8]. The cost of genotypic methods and their
requirement for trained personnel mean that, to
date, they have not gained wide use in clinical
mycobacteriology laboratories, especially in
developing countries where the TB situation and
MDRTB are of major concern.
New approaches based on liquid culture have
also been developed to speed-up detection of
mycobacterial growth, and these have been used
both for initial diagnosis and for detection of drug
resistance. Such systems include the BACTEC
TB-460 radiometric system (Becton Dickinson,
Sparks, MD, USA) and, more recently, the myco-
bacterial growth indicator tube (MGIT) (Becton
Dickinson) in both its manual and automated
versions [9–11]. These methods detect metabolic
activity of mycobacteria, as opposed to mycobac-
terial growth as colonies on a solid medium.
Using the same approach, several techniques
that use colourimetric detection of mycobacterial
growth have recently been proposed; these tech-
niques have mostly been used for the rapid
detection of drug resistance, and have been
proposed as rapid susceptibility testing methods
that are appropriate for low-resource high-burden
countries. This review describes the development,
evaluation and application of rapid colourimetric
methods for detection of drug resistance in
M. tuberculosis, and comments on the feasibility
of their implementation on a routine basis in
diagnostic mycobacteriology laboratories in coun-
tries with a high endemicity of TB.
DEVELOPMENT OF COLOURIMETRIC
METHODS TO DETECT DRUG
RESISTANCE IN M. TUBERCULOSIS
Colourimetric methods for detecting drug resist-
ance in M. tuberculosis are generally based on the
reduction of an oxidation–reduction indicator
added to a liquid culture medium after M. tuber-
culosis has been exposed in vitro to different
antibiotics. Resistance is detected by a change in
colour of the oxidation–reduction indicator,
which is directly proportional to the number of
viable mycobacteria in the medium [12]. More
recently, another simple format, the nitrate reduc-
tase assay (NRA), has also been proposed as a
rapid method for detecting drug resistance in TB
[13]. This method is based on the capacity of
M. tuberculosis to reduce nitrate to nitrite, which
can easily be detected in a coloured reaction.
COLOURIMETRIC DETECTION
METHODS BASED ON REDOX
INDICATORS
One of the first redox indicators to be used for
detecting drug resistance in M. tuberculosis was
Alamar blue (Trek Diagnostics, Westlake, OH,
USA). This approach was first proposed by Yajko
et al. [12] in a study that evaluated the activity of
the first-line anti-tuberculosis drugs isoniazid,
rifampicin, ethambutol and streptomycin against
clinical isolates of M. tuberculosis. Alamar blue is a
proprietary reagent that had been used previ-
ously to study metabolism and viability in other
microorganisms [14,15], and to measure toxicity
in prokaryotic and eukaryotic cells [16]. It is blue
in colour in the oxidised state, but turns pink
when reduced as a result of bacterial metabolism,
with the two colours being differentiated easily
with the naked eye. The study of Yajko et al. [12]
was important, since it showed for the first time
that MICs of isoniazid, rifampicin, streptomycin
and ethambutol could be determined after incu-
bation of M. tuberculosis isolates for only
1–2 weeks in the presence of antibiotics. When
compared with results obtained using the agar
proportion method, a higher level of resistance
according to Alamar blue reduction was always
associated with higher MICs, and the overall
agreement between the two methods was 97%.
The Alamar blue colourimetric method was
also proposed by Collins and Franzblau [17] for
use in a microplate format for high-throughput
screening of compounds against M. tuberculosis
and Mycobacterium avium, and by Shawar et al.
[18] for rapid screening of natural products
for anti-mycobacterial activity. In the study by
Collins and Franzblau [17], a microplate Alamar
blue assay was used to determine the MICs of 30
antimicrobial agents, with both visual and fluor-
ometric readings, in comparison with MICs
obtained using the BACTEC 460 system. In the
second study, Shawar et al. [18] used Alamar blue
as an alternative method for detecting anti-myco-
bacterial activity against recombinant strains of
Mycobacterium bovis BCG and Mycobacterium intra-
cellulare in plant extracts. Both studies confirmed
the usefulness of the Alamar blue colourimetric
method for screening for anti-mycobacterial
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compounds. In another study by Franzblau et al.
[19], the microplate Alamar blue assay was
used to determine MICs of isoniazid, rifampicin,
streptomycin and ethambutol for clinical isolates
of M. tuberculosis taken directly from solid media,
with results available within 8 days.
A simplified version of the test was introduced
by Palomino and Portaels [20], who used a single
critical concentration of each drug in a microtitre
format to investigate clinical isolates. Several
other studies have successfully used Alamar blue
to detect drug resistance in M. tuberculosis [21,22],
to monitor treatment in pulmonary TB patients
[23] and, most recently, to assess the anti-myco-
bacterial activity of several plant extracts and
modified antibiotic molecules [24,25].
An important advance was achieved by
O’Brien et al. [26] while assessing cytotoxicity in
mammalian cells. By nucleic magnetic resonance
and mass spectrometry analysis, it was demon-
strated that Alamar blue and resazurin were the
same compounds. Resazurin is an oxidation–
reduction indicator that had been used previously
in the ‘resazurin reduction test’ to assess cell
viability and bacterial contamination, and to test
for antimicrobial activity [27–29]. This informa-
tion was used by Palomino et al. [30] to introduce
a resazurin-based assay to detect multidrug
resistance in M. tuberculosis. The resazurin micro-
titre assay (REMA), performed in a 96-well plate,
was able to detect MDRTB strains after incubation
for 7 days in the presence of isoniazid and
rifampicin. A sensitivity of 100% for isoniazid
and rifampicin, and specificities of 96.2% and
100% for isoniazid and rifampicin, respectively,
were obtained when compared with the reference
standard proportion method for detecting resist-
ance in Lo¨wenstein–Jensen (LJ) medium. As with
the microplate Alamar blue assay, the REMA
plate could also be used to determine MICs. Banfi
et al. [31] obtained similar good results in a study
that used resazurin to evaluate the susceptibility
of M. tuberculosis isolates to first-line drugs. The
REMA plate was later adapted for rapid detection
of resistance to second-line drugs, with a specif-
icity of 100% and a sensitivity that ranged from
96.8% to 100% [32], and to quinolones, with a
sensitivity and specificity of 100% [33]. Most
recently, the REMA plate has been employed in a
modified assay that uses nicotinamide to detect
resistance to pyrazinamide, which is an anti-
tuberculosis drug that is not easy to test in vitro,
since it is only active at an acid pH [34]. The test
showed excellent agreement (sensitivity of 100%
and specificity of 98%) with the pyrazinamidase
method of Wayne [35] and the BACTEC system at
acid pH, which are the only two methods avail-
able to test pyrazinamide activity. The main
advantages of using resazurin as an indicator of
growth are that it is a non-proprietary reagent
and is very easy to obtain at very low cost, which
is a very important consideration in the introduc-
tion of this type of technique into low-resource
countries.
Several other studies have been published
concerning the application of resazurin to the
rapid detection of drug resistance in TB [36–39].
A modification of the technique has been pro-
posed by Coban et al. [40], who performed the
REMA as a macro-method in screw-cap tubes,
with a sensitivity and specificity of 100% and
91.7%, respectively, for detecting isoniazid
resistance, and sensitivity and specificity of
100% for detection of rifampicin resistance,
thereby reducing the risk of aerosol generation
[40]. In all the studies performed to date, the
REMA plate and its modifications have per-
formed very well in comparison with the refer-
ence standard method for the detection of drug
resistance, showing both high accuracy and ease
of interpretation.
COLOURIMETRIC DETECTION
METHODS BASED ON TETRAZOLIUM
SALTS
Several tetrazolium salts have been assayed for
possible use in drug susceptibility testing and
rapid drug resistance detection in cases of TB. Of
these compounds, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) has
been used most widely. MTT is a yellow com-
pound in the oxidised state but, when reduced
by metabolically active cells, it produces insol-
uble purple MTT formazan crystals that, after
solubilisation, can be measured with a spectro-
photometer. MTT has been used previously to
assess the viability of cells [41]. This compound
was first suggested by Mshana and colleagues
[42,43] for use in a colourimetric assay for rapid
detection of rifampicin resistance. These studies
showed that there was a linear relationship
between the number of viable mycobacteria and
the ability to reduce MTT. These experiments
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were performed in tubes, with the reduction of
MTT to blue formazan being quantified with a
spectrophotometer after incubation for 6 days,
but were also interpreted visually. The results
obtained for 92 clinical isolates of M. tuberculosis
matched completely with those obtained using
the reference standard BACTEC radiometric
method. Although highly accurate, the test was
only standardised for detection of rifampicin
resistance. More recently, the method was
slightly modified to allow interpretation of both
rifampicin and isoniazid resistance by reading
results at 4 and 7 days, respectively. The sensi-
tivity and specificity remained high (92.3% and
99.5%, respectively) when compared with the
proportion method [44].
In order to implement a rapid and inexpensive
method for determining the MICs of several
drugs for MDRTB, the MTT assay has also been
formatted as a microplate-based test and evalu-
ated with clinical isolates of M. tuberculosis. A
good correlation was obtained in comparison
with the proportion method in 7H11 agar when
testing for susceptibility to kanamycin, capreo-
mycin, ethionamide, p-aminosalicylic acid,
clarithromycin, cycloserine, clofazimine, levo-
floxacin and rifabutin [45]. Several other studies
have used the MTT assay for rapid detection of
drug resistance to first-line drugs, with good
results [36,37,46]. More recently, and with the
purpose of speeding up detection of drug resist-
ance in clinical samples, the MTT assay has been
applied directly to sputum samples for detection
of rifampicin resistance. The sensitivity and spe-
cificity of this direct MTT assay matched those of
the standard indirect assay on 7H10 agar, with
98.5% of the samples giving interpretable results
within 2 weeks [47].
Two other tetrazolium salts have also been
suggested for use in rapid susceptibility tests
of M. tuberculosis. De Logu et al. [48,49] used
2,3-bis(2-methoxy-4-nitro-5-sulphophenyl)-2H-
tetrazolium-5-carboxanilide in a rapid test to assess
the susceptibility of clinical isolates of M. tubercu-
losis to several drugs, including isoniazid and
rifampicin, and compared the results to those
obtained using the agar dilution method recom-
mended by the CLSI. The percentage agreement
between the tests was very high. The same group
also evaluated the tetrazolium salt 2,3,5-triphenyl-
tetrazolium chloride in a similar colourimetric test,
but good results were not obtained [50].
COLOURIMETRIC DETECTION
METHOD BASED ON THE NITRATE
REDUCTASE ASSAY
A new approach for the rapid colourimetric
detection of drug resistance in TB involves the
NRA, which is based on the capacity of M. tuber-
culosis to reduce nitrate to nitrite. The NRA, also
known as the Griess method, is an old technique
that has been used to differentiate M. tuberculosis
from other mycobacterial species [6]. A reap-
praisal of this technique allowed its introduction
as a rapid method for detecting drug resistance in
TB [13]. By incorporation of potassium nitrate in
the culture medium, reduction of nitrate can be
detected using specific reagents, which produce a
coloured reaction. When a panel of M. tuberculosis
strains with various resistance patterns was tested,
the sensitivity and specificity of the NRA, com-
pared with the BACTEC 460-TB system, were
100% and 100% for rifampicin, 97% and 96% for
isoniazid, 95% and 83% for streptomycin, and
75% and 98% for ethambutol, respectively. The
majority of results were available after incubation
for 7 days. The NRA was able to identify most
resistant and susceptible strains correctly. In an
attempt to simplify and expediate results, the
NRA has also been performed in a liquid medium,
with good results for isoniazid and rifampicin,
but lower agreement for both ethambutol and
streptomycin, when compared with the BACTEC
460-TB system [51,52]. A microplate-based NRA
has also been evaluated with M. tuberculosis iso-
lates in comparison with the proportion method
and the Alamar blue assay [53].
Two recent studies have described the use of the
NRA directly with sputum samples. Musa et al.
[54] evaluated the NRA for drug susceptibility
testing ofM. tuberculosisdirectly on smear-positive
sputum samples containing more than ten acid-fast
bacilli per microscopy field. Sensitivity and spe-
cificity, compared with the direct proportion
method, were 100% and 100%, 93% and 100%,
76% and 100%, and 55% and 99% for rifampicin,
isoniazid, streptomycin and ethambutol, respect-
ively, with results available in most cases within
14 days. A similar study by Solis et al. [55] com-
pared the sensitivity and specificity of the direct
NRA with the proportion method in LJ medium for
determining resistance to isoniazid and rifampicin
among clinical specimens. In this case, the sensi-
tivity and specificity of the NRA were 99.1% and
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100%, and 93.5% and 100% for isoniazid and
rifampicin resistance, respectively. These two
studies have shown the feasibility of implementing
the NRA as a direct method for detecting drug-
resistant M. tuberculosis in sputum samples.
These findings warrant further studies in target
populations.
Table 1 summarises the major studies per-
formed using colourimetric methods for the
detection of drug resistance in M. tuberculosis.
VALIDATION OF COLOURIMETRIC
METHODS FOR THE RAPID
DETECTION OF DRUG RESISTANCE
IN M. TUBERCULOSIS
For the validation of new tests, it is recommended
that studies should be evaluated in the target
populations for the tests [56]. An important step
towards this goal is the performance of multicen-
tre studies in different settings. The main objec-
tives of these multicentre studies should be to
assess the performance of the test, as well as some
of its operational characteristics. Following the
introduction of colourimetric methods using
redox indicators and the NRA, a few studies
have been performed with the purpose of valid-
ating these techniques in different settings and
comparing them with other methods used rou-
tinely in the laboratory. Thus, Lemus et al. [36]
studied the performance of colourimetric meth-
ods using MTT, resazurin and nitrate reduction
for the detection of rifampicin resistance in a
panel of 20 coded M. tuberculosis strains tested
blind. The results obtained were compared with
those of the reference standard methods, i.e.,
the proportion method on LJ medium and the
BACTEC TB-460 system. The results were also
compared with those of the two commercially
available tests: the MGIT system (Becton Dickin-
son) and the INNO LiPA Rif.TB kit (Innogenetics,
Ghent, Belgium). Complete agreement was ob-
tained among all methods. Another study by
Montoro et al. [37] validated the same three
techniques with 100 M. tuberculosis clinical iso-
lates, and compared the results with those
obtained using the reference standard proportion
method on LJ medium [37]. Again, a high level of
Table 1. Major studies using
colourimetric methods for detection
of drug resistance in Mycobacterium
spp.
Reference Indicator Performed on Antibiotics
Yajko et al. [12] Alamar blue Clinical isolates RIF, INH, SM, EMB
Collins et al. [17] Alamar blue M. tuberculosis 30 antimicrobial agents
M. avium
Shawar et al. [18] Alamar blue M. bovis Natural products
M. intracellulare
Franzblau et al. [19] Alamar blue Clinical isolates RIF, INH, SM, EMB
Palomino and Portaels [20] Alamar blue Clinical isolates RIF, INH, SM, EMB
Bastian et al. [21] Alamar blue Clinical isolates KM
Pracharktam et al. [22] Alamar blue Clinical isolates OFX, LVX
Mshana et al. [42] MTT Clinical isolates RIF
Abate et al. [43] MTT Clinical isolates RIF
Foongladda et al. [44] MTT Clinical isolates RIF, INH
Morcillo et al. [45] MTT Clinical isolates Nine antibiotics
Abate et al. [47] MTT Sputum samples RIF
Lemus et al. [36] MTT Clinical isolates RIF
Montoro et al. [37] MTT Clinical isolates INH, RIF, SM, EMB
Martin et al. [57] MTT Clinical isolates INH, RIF, SM, EMB
Palomino et al. [30] Resazurin Clinical isolates RIF, INH
Martin et al. [32] Resazurin Clinical isolates ETH, KM, CAP, OFX, PAS
Lemus et al. [36] Resazurin Clinical isolates RIF
Montoro et al. [37] Resazurin Clinical isolates INH, RIF, SM, EMB
Martin et al. [33] Resazurin Clinical isolates OFX
Martin et al. [57] Resazurin Clinical isolates INH, RIF, SM, EMB
Martin et al. [34] Resazurin Clinical isolates PZA
Coban et al. [40] Resazurin Clinical isolates INH, RIF
Nateche et al. [39] Resazurin Clinical isolates INH, RIF
Umubyeyi et al. [38] Resazurin Clinical isolates OFX
Angeby et al. [13] NRA Clinical isolates INH, RIF, SM, EMB
Syre et al. [51] NRA Clinical isolates INH, RIF
Syre et al. [52] NRA Clinical isolates EMB, SM
Lemus et al. [36] NRA Clinical isolates RIF
Montoro et al. [37] NRA Clinical isolates INH, RIF, SM, EMB
Martin et al. [58] NRA Clinical isolates INH, RIF, SM, EMB
Kumar et al. [53] NRA Clinical isolates INH, RIF, EMB
Musa et al. [54] NRA Sputum samples INH, RIF, SM, EMB
Solis et al. [55] NRA Sputum samples INH, RIF
MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; NRA, nitrate reductase assay; INH, isoniazid;
RIF, rifampicin; SM, streptomycin; EMB, ethambutol; KM, kanamycin; OFX, ofloxacin; LVX, levofloxacin; ETH,
ethionamide; CAP, capreomycin; PAS, p-aminosalicylic acid; PZA, pyrazinamide.
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agreement was obtained for the detection of
rifampicin and isoniazid resistance. There was
also a high level of agreement among the colour-
imetric methods and the reference standard pro-
portion method for the rapid detection of
rifampicin and isoniazid resistance; however, a
low specificity was obtained for detection of
streptomycin and ethambutol resistance by the
REMA and MTT tests. In contrast, the NRA
showed good agreement for all drugs tested.
To date, only two multicentre studies have
assessed the performance and operational char-
acteristics of these colourimetric methods. Martin
et al. [57] performed a multicentre study to assess
the MTT and resazurin colourimetric methods for
rapid drug susceptibility testing of first-line anti-
TB antibiotics. The study was performed at seven
laboratories in Latin America. Each site received
30 coded M. tuberculosis strains and performed
the MTT and resazurin colourimetric assays blind
with rifampicin, isoniazid, ethambutol and strep-
tomycin. The MICs obtained were compared with
the conventional proportion method on LJ med-
ium. Excellent results were reported for rifampi-
cin, isoniazid and ethambutol, with levels of
specificity and sensitivity of 96–99%. The second
multicentre study [58] performed an evaluation of
the NRA method at five laboratories in different
countries, and compared the results with those
obtained using the reference standard proportion
method on LJ medium. The NRA was highly
accurate in detecting resistance to rifampicin,
isoniazid and ethambutol, with accuracies of
98%, 96.6% and 97.9%, respectively. The assay
was easy to implement in countries with limited
laboratory facilities. However, both studies
showed reduced accuracy for detecting resist-
ance to streptomycin. The quality assurance
programme for M. tuberculosis drug susceptibility
testing of the WHO ⁄ IUATLD has proposed a
minimum efficiency of 92% for streptomycin,
which was not reached in these studies [59].
Further standardisation is necessary in order to




To date, most studies have been performed with
cultured M. tuberculosis isolates, and only a few
studies have used the tests directly with clinical
specimens. It is increasingly recognised that the
proper implementation of these new methods
requires that they should be evaluated in well-
designed and controlled diagnostic clinical trials,
and also tested in high-endemicity low-resource
settings in which the implementation and use of
these methods are most needed. There are several
previous examples of diagnostic tests that per-
formed very well when they were first developed,
but then gave disappointing results when tested
in their target population [60]. In addition, several
common errors in the design and reporting of
diagnostic trials in TB have been identified,
including the selection criteria for sampling and
the sample size, the reporting of positive and
negative predictive values without taking into
consideration the population for which the test
was intended, the use of an inadequate reference
standard, and the failure to state when the test
under study is indicated for use [60]. For these
reasons, it is proposed that these studies should
be carefully performed following a multi-phase
sequence, as currently exists for drug and vaccine
development. A phase I study would involve the
pre-clinical test development; phase II would
perform proof-of-principle studies that could
distinguish a positive from a negative sample in
easily accessible populations; phase III should
demonstrate the performance of the test in a
target population; and phase IV should study the
cost-effectiveness and impact of the new tests in
comparison with existing methods [61]. Further-
more, as has been stressed previously, efforts
should be made to implement good laboratory
practice and good clinical practice in well-de-
signed diagnostic trials for the proper evaluation
of these new tests [56]. To date, colourimetric
methods for rapid detection of drug resistance in
TB have completed half of this process, and are
now poised to enter into the last phases of
evaluation to assess their performance more
carefully in target populations and to examine
their impact on the management of the disease.
FINAL REMARKS
In the quest for alternative methods to detect drug
resistance in cases of TB, colourimetric methods
based on the use of redox indicators and the nitrate
reduction test have gained increasing acceptance
because of their simplicity and the absence of any
requirement for sophisticated equipment and
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highly trained personnel. Several different studies
and evaluations have shown a high degree of
accuracy in comparison with the reference stand-
ard methods, especially for detection of resistance
to rifampicin and isoniazid, the two most import-
ant drugs in the treatment of TB. The new methods
seem to be good options for clinical mycobacteri-
ology laboratories, and especially for those labor-
atories that lack access to other more sophisticated,
rapid molecular techniques, as is often the case in
laboratories in limited-resource countries. One
caveat concerning colourimetric tests using a
microtitre plate format is that they may pose a
biosafety hazard, since the manipulation of plates
could generate aerosols; for this reason, these tests
are more appropriate for use in reference laborat-
ories. Further issues remain to be addressed as part
of well-designed phase III and phase IV diagnostic
trials before these new methods can be considered
for implementation as part of TB control pro-
grammes.
ACKNOWLEDGEMENTS
The authors’ studies received financial support from the EC
INCO Programme (Contract No. ICA4-CT-2001-10087), EC
LIFESCIHEALTH-3 (Contract no. 516028), Damien Foundation
(Brussels, Belgium) and Fund for Scientific Research (Flanders,
Belgium).
REFERENCES
1. World Health Organisation. Global tuberculosis control:
surveillance, planning, financing, WHO ⁄HTM ⁄TB ⁄ 2006.362.
Geneva: World Health Organisation, 2006.
2. Barnes PF, Lakey DL, Burman WJ. Tuberculosis in patients
with HIV infection. Infect Dis Clin North Am 2002; 16: 107–
126.
3. World Health Organisation. Anti-tuberculosis drug resistance
in the world. Third global report, WHO ⁄HTM ⁄TB ⁄ 2004.
343. Geneva: World Health Organisation, 2004.
4. Centers for Disease Control and Prevention (CDC).
Emergence of Mycobacterium tuberculosis with extensive
resistance to second-line drugs—worldwide, 2000–2004.
MMWR 2006; 55: 301–305.
5. Masjedi MR, Farnia P, Sorooch S et al. Extensively drug-
resistant tuberculosis: 2 years of surveillance in Iran. Clin
Infect Dis 2006; 43: 841–847.
6. Kent TK, Kubica GP. Public Health mycobacteriology: a guide
for level III laboratories. Atlanta: Centers for Disease Con-
trol, 1985.
7. Garcia de Viedma D. Rapid detection of resistance in
Mycobacterium tuberculosis: a review discussing molecular
approaches. Clin Microbiol Infect 2003; 9: 349–359.
8. Palomino JC. Newer diagnostics for tuberculosis and
multi-drug resistant tuberculosis. Curr Opin Pulm Med
2006; 12: 172–178.
9. Roberts GD, Goodman NL, Heifets L et al. Evaluation of
the BACTEC radiometric method for recovery of myco-
bacteria and drug susceptibility testing of Mycobacterium
tuberculosis from acid-fast smear-positive specimens. J Clin
Microbiol 1983; 18: 689–696.
10. Palomino JC, Traore H, Fissette K, Portaels F. Evaluation
of Mycobacteria Growth Indicator Tube (MGIT) for drug
susceptibility testing of Mycobacterium tuberculosis. Int J
Tuberc Lung Dis 1999; 3: 344–348.
11. Johansen IS, Thomsen VO, Marjamaki M, Sosnovskaja A,
Lundgren B. Rapid, automated, non-radiometric suscep-
tibility testing of Mycobacterium tuberculosis complex to
four first-line anti-tuberculous drugs used in standard
short-course chemotherapy. Diagn Microbiol Infect Dis
2004; 50: 103–107.
12. Yajko DM, Madej JJ, Lancaster MV et al. Colorimetric
method for determining MICs of antimicrobial agents for
Mycobacterium tuberculosis. J Clin Microbiol 1995; 33: 2324–
2327.
13. Angeby KA, Klintz L, Hoffner SE. Rapid and inexpensive
drug susceptibility testing of Mycobacterium tuberculosis
with a nitrate reductase assay. J Clin Microbiol 2002; 40:
553–555.
14. Novak SM, Hindler J, Bruckner DA. Reliability of two
novel methods, Alamar and Etest, for detection of methi-
cillin-resistant Staphylococcus aureus. J Clin Microbiol 1993;
31: 3056–3057.
15. Pfaller MA, Barry AL. Evaluation of a novel colorimetric
broth microdilution method for antifungal susceptibility
testing of yeast isolates. J Clin Microbiol 1994; 32: 1992–
1996.
16. Ahmed SA, Gogal RM Jr, Walsh JE. A new rapid and
simple non-radioactive assay to monitor and determine
the proliferation of lymphocytes: an alternative to (3H)
thymidine incorporation assay. J Immunol Methods 1994;
170: 211–224.
17. Collins L, Franzblau SG. Microplate alamar blue assay
versus BACTEC 460 system for high-throughput screening
of compounds against Mycobacterium tuberculosis and
Mycobacterium avium. Antimicrob Agents Chemother 1997; 41:
1004–1009.
18. Shawar RM, Humble DJ, Van Dalfsen JM et al. Rapid
screening of natural products for antimycobacterial
activity by using luciferase-expressing strains of Mycobac-
terium bovis BCG and Mycobacterium intracellulare. Anti-
microb Agents Chemother 1997; 41: 570–574.
19. Franzblau SG, Witzig RS, McLaughlin JC et al. Rapid, low-
technology MIC determination with clinical Mycobacterium
tuberculosis isolates by using the microplate Alamar Blue
assay. J Clin Microbiol 1998; 36: 362–366.
20. Palomino JC, Portaels F. Simple procedure for drug sus-
ceptibility testing of Mycobacterium tuberculosis using a
commercial colorimetric assay. Eur J Clin Microbiol Infect
Dis 1999; 18: 380–383.
21. Bastian I, Rigouts L, Palomino JC, Portaels F. Kanamycin
susceptibility testing of Mycobacterium tuberculosis using
Mycobacterium Growth Indicator Tube and a colori-
metric method. Antimicrob Agents Chemother 2001; 45:
1934–1936.
22. Pracharktam R, Angkananukool K, Vibhagool A. In vitro
susceptibility testing of levofloxacin and ofloxacin by
microtiter plate Alamar blue against multidrug and non
760 Clinical Microbiology and Infection, Volume 13 Number 8, August 2007
 2007 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 754–762
multidrug resistant Mycobacterium tuberculosis in Thailand.
J Med Assoc Thai 2001; 84: 1241–1245.
23. Farnia P, Mohammadi F, Mirsaedi M et al. Bacteriological
follow-up of pulmonary tuberculosis treatment: a study
with a simple colorimetric assay. Microbes Infect 2004; 6:
972–976.
24. Akihisa T, Franzblau SG, Ukiya M et al. Antitubercular
activity of triterpenoids from Asteraceae flowers. Biol
Pharm Bull 2005; 28: 158–160.
25. Sriram D, Yogeeswari P, Madhu K. Synthesis and in vitro
and in vivo antimycobacterial activity of isonicotinoyl
hydrazones. Bioorg Med Chem Lett 2005; 15: 4502–4505.
26. O’Brien J, Wilson I, Orton T, Pognan F. Investigation of the
Alamar Blue (resazurin) fluorescent dye for the assessment
of mammalian cell cytotoxicity. Eur J Biochem 2000; 267:
5421–5426.
27. Carter RA, Ericsson SA, Corn CD et al. Assessing the
fertility potential of equine semen samples using the
reducible dyes methylene green and resazurin. Arch
Androl 1998; 40: 59–66.
28. Mann CM, Markham JL. A new method for determining
the minimum inhibitory concentration of essential oils.
J Appl Microbiol 1998; 84: 538–544.
29. Smith CF, Townsend DE. A new medium for determining
the total plate count in food. J Food Prot 1999; 62: 1404–
1410.
30. Palomino JC, Martin A, Camacho M, Guerra H, Swings J,
Portaels F. Resazurin microtiter assay plate: simple and
inexpensive method for detection of drug resistance in
Mycobacterium tuberculosis. Antimicrob Agents Chemother
2002; 46: 2720–2722.
31. Banfi E, Scialino G, Monti-Bragadin C. Development of a
microdilution method to evaluate Mycobacterium tubercu-
losis drug susceptibility. J Antimicrob Chemother 2003; 52:
796–800.
32. Martin A, Camacho M, Portaels F, Palomino JC. Resazurin
microtiter assay plate testing of Mycobacterium tuberculosis
susceptibilities to second-line drugs: rapid, simple, and
inexpensive method. Antimicrob Agents Chemother 2003; 47:
3616–3619.
33. Martin A, Palomino JC, Portaels F. Rapid detection of
ofloxacin resistance in Mycobacterium tuberculosis by two
low-cost colorimetric methods: resazurin and nitrate
reductase assays. J Clin Microbiol 2005; 43: 1612–1616.
34. Martin A, Takiff H, Vandamme P, Swings J, Palomino JC,
Portaels F. A new rapid and simple colorimetric method to
detect pyrazinamide resistance in Mycobacterium tubercu-
losis using nicotinamide. J Antimicrob Chemother 2006; 58:
327–331.
35. Wayne LG. Simple pyrazinamidase and urease tests for
routine identification on mycobacteria. Am Rev Respir Dis
1974; 109: 147–151.
36. Lemus D, Martin A, Montoro E, Portaels F, Palomino JC.
Rapid alternative methods for detection of rifampicin
resistance in Mycobacterium tuberculosis. J Antimicrob
Chemother 2004; 54: 130–133.
37. Montoro E, Lemus D, Echemendia M, Martin A, Portaels
F, Palomino JC. Comparative evaluation of the nitrate
reduction assay, the MTT test, and the resazurin microtitre
assay for drug susceptibility testing of clinical isolates of
Mycobacterium tuberculosis. J Antimicrob Chemother 2005; 55:
500–505.
38. Umubyeyi AN, Martin A, Zissis G, Struelens M, Karita E,
Portaels F. Evaluation of the resazurin microtiter assay for
rapid detection of ofloxacin resistance in M. tuberculosis.
Int J Tuberc Lung Dis 2006; 10: 808–811.
39. Nateche F, Martin A, Baraka S, Palomino JC, Khaled S,
Portaels F. Application of the resazurin microtitre assay
for detection of multidrug resistance in Mycobacterium
tuberculosis in Algiers. J Med Microbiol 2006; 55: 857–860.
40. Coban AY, Cekic Cihan C, Bilgin K et al. Rapid suscepti-
bility test for Mycobacterium tuberculosis to isoniazid and
rifampin with resazurin method in screw-cap tubes.
J Chemother 2006; 18: 140–143.
41. Mosmann T. Rapid colorimetric assay for cellular growth
and survival: application to proliferation and cytotoxicity
assays. J Immunol Methods 1983; 65: 55–63.
42. Mshana RN, Tadesse G, Abate G, Miorner H. Use of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
for rapid detection of rifampin-resistant Mycobacterium
tuberculosis. J Clin Microbiol 1998; 36: 1214–1219.
43. Abate G, Mshana RN, Miorner H. Evaluation of a
colorimetric assay based on 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) for rapid detec-
tion of rifampicin resistance in Mycobacterium tuberculosis.
Int J Tuberc Lung Dis 1998; 2: 1011–1016.
44. Foongladda S, Roengsanthia D, Arjrattanakool W, Chu-
chottaworn C, Chaiprasert A, Franzblau SG. Rapid and
simple MTT method for rifampicin and isoniazid suscep-
tibility testing of Mycobacterium tuberculosis. Int J Tuberc
Lung Dis 2002; 6: 1118–1122.
45. Morcillo N, Di Giulio B, Testani B, Pontino M, Chirico C,
Dolmann A. A microplate indicator-based method for
determining the susceptibility of multidrug-resistant
Mycobacterium tuberculosis to antimicrobial agents. Int J
Tuberc Lung Dis 2004; 8: 253–259.
46. Caviedes L, Delgado J, Gilman RH. Tetrazolium micro-
plate assay as a rapid and inexpensive colorimetric
method for determination of antibiotic susceptibility of
Mycobacterium tuberculosis. J Clin Microbiol 2002; 40: 1873–
1874.
47. Abate G, Aseffa A, Selassie A et al. Direct colorimetric
assay for rapid detection of rifampin-resistant Mycobacte-
rium tuberculosis. J Clin Microbiol 2004; 42: 871–873.
48. De Logu A, Pellerano ML, Sanna A, Pusceddu MC, Uda P,
Saddi B. Comparison of the susceptibility testing of clin-
ical isolates of Mycobacterium tuberculosis by the XTT
colorimetric method and the NCCLS standard method. Int
J Antimicrob Agents 2003; 21: 244–250.
49. De Logu A, Borgna R, Uda P, Sanna A, Pellerano ML,
Saddi B. The 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxanilide (XTT) assay as rapid colori-
metric method for determination of antibiotic susceptibility
of clinical Mycobacterium tuberculosis isolates in liquid
medium. Clin Lab 2003; 49: 357–365.
50. De Logu A, Uda P, Pellerano ML, Pusceddu MC, Saddi B,
Schivo ML. Comparison of two rapid colorimetric meth-
ods for determining resistance of Mycobacterium tubercu-
losis to rifampin, isoniazid, and streptomycin in liquid
medium. Eur J Clin Microbiol Infect Dis 2001; 20: 33–39.
51. Syre H, Phyu S, Sandven P, Bjorvatn B, Grewal HM. Rapid
colorimetric method for testing susceptibility of Myco-
bacterium tuberculosis to isoniazid and rifampin in liquid
cultures. J Clin Microbiol 2003; 41: 5173–5177.
Palomino et al. Colourimetric methods for detecting drug resistance 761
 2007 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 754–762
52. Syre H, Valvatne H, Sandven P, Grewal HM. Evaluation of
the nitrate-based colorimetric method for testing the sus-
ceptibility of Mycobacterium tuberculosis to streptomycin
and ethambutol in liquid cultures. J Antimicrob Chemother
2006; 57: 987–991.
53. Kumar M, Khan IA, Verma V, Qazi GN. Microplate nitrate
reductase assay versus Alamar Blue assay for MIC deter-
mination of Mycobacterium tuberculosis. Int J Tuberc Lung
Dis 2005; 9: 939–941.
54. Musa HR, Ambroggi M, Souto A, Angeby KA. Drug sus-
ceptibility testing of Mycobacterium tuberculosis by a nitrate
reductase assay applied directly on microscopy-positive
sputum samples. J Clin Microbiol 2005; 43: 3159–3161.
55. Solis LA, Shin SS, Han LL, Llanos F, Stowell M, Sloutsky
A. Validation of a rapid method for detection of M.
tuberculosis resistance to isoniazid and rifampin in Lima,
Peru. Int J Tuberc Lung Dis 2005; 9: 760–764.
56. TDR Diagnostics Evaluation Expert Panel. Evaluation of
diagnostic tests for infectious diseases: general principles.
Nat Rev Microbiol 2006; 4: 521–533.
57. Martin A, Morcillo N, Lemus D et al. Multicenter study of
MTT and resazurin assays for testing susceptibility to first-
line anti-tuberculosis drugs. Int J Tuberc Lung Dis 2005; 9:
901–906.
58. Martin A, Montoro E, Lemus D et al. Multicenter evalua-
tion of the nitrate reductase assay for drug resistance
detection of Mycobacterium tuberculosis. J Microbiol Methods
2005; 63: 145–150.
59. Laszlo A, Rahman M, Espinal M et al. Quality assurance
programme for drug susceptibility testing of Mycobacte-
rium tuberculosis in the WHO ⁄ IUATLD Supranational
Reference Laboratory Network: five rounds of proficiency
testing, 1994–1998. Int J Tuberc Lung Dis 2002; 6: 748–756.
60. Small PM, Perkins MD. More rigour needed in trials of
new diagnostic agents for tuberculosis. Lancet 2000; 356:
1048–1049.
61. van der Schouw YT, Verbeek AL, Ruijs SH. Guidelines for
the assessment of new diagnostic tests. Invest Radiol 1995;
30: 334–340.
762 Clinical Microbiology and Infection, Volume 13 Number 8, August 2007
 2007 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 754–762
